NASDAQ:AGEN Agenus (AGEN) Stock Price, News & Analysis $2.83 +0.07 (+2.54%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Agenus Stock (NASDAQ:AGEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Agenus alerts:Sign Up Key Stats Today's Range$2.66▼$2.9150-Day Range$2.57▼$4.7352-Week Range$2.50▼$19.69Volume790,404 shsAverage Volume642,221 shsMarket Capitalization$66.39 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company OverviewAgenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Read More… Agenus Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks72nd Percentile Overall ScoreAGEN MarketRank™: Agenus scored higher than 72% of companies evaluated by MarketBeat, and ranked 278th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingAgenus has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageAgenus has only been the subject of 1 research reports in the past 90 days.Read more about Agenus' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Agenus are expected to grow in the coming year, from ($12.93) to ($9.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agenus is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agenus is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.34% of the float of Agenus has been sold short.Short Interest Ratio / Days to CoverAgenus has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Agenus has recently increased by 4.96%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAgenus does not currently pay a dividend.Dividend GrowthAgenus does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.93 Percentage of Shares Shorted12.34% of the float of Agenus has been sold short.Short Interest Ratio / Days to CoverAgenus has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Agenus has recently increased by 4.96%, indicating that investor sentiment is decreasing. News and Social Media1.9 / 5News Sentiment0.45 News SentimentAgenus has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Agenus this week, compared to 6 articles on an average week.Search InterestOnly 15 people have searched for AGEN on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.MarketBeat Follows5 people have added Agenus to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Agenus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Agenus is held by insiders.Percentage Held by Institutions61.46% of the stock of Agenus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Agenus' insider trading history. Receive AGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter. Email Address AGEN Stock News HeadlinesAnalysts Set Agenus Inc. (NASDAQ:AGEN) PT at $10.00December 19, 2024 | americanbankingnews.comAgenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric CancersDecember 18, 2024 | businesswire.comNo one’s talking about these Trump tradesAs you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”December 23, 2024 | Insiders Exposed (Ad)Vaccine Adjuvants Market with Business Strategy, Key Drivers, Opportunities, Top Key Companies Analysis and ForecastDecember 13, 2024 | theglobeandmail.comTanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With AgenusDecember 12, 2024 | finance.yahoo.comAgenus Hold Rating: Strategic Focus on MSS-CRC Amid Financial and Regulatory UncertaintiesDecember 6, 2024 | markets.businessinsider.comAgenus announces strategic realignmentDecember 6, 2024 | markets.businessinsider.comAgenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce CostsDecember 5, 2024 | businesswire.comSee More Headlines AGEN Stock Analysis - Frequently Asked Questions How have AGEN shares performed this year? Agenus' stock was trading at $16.5580 at the beginning of 2024. Since then, AGEN shares have decreased by 82.9% and is now trading at $2.83. View the best growth stocks for 2024 here. How were Agenus' earnings last quarter? Agenus Inc. (NASDAQ:AGEN) posted its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by $1.19. The biotechnology company had revenue of $23.51 million for the quarter, compared to analysts' expectations of $64.73 million. When did Agenus' stock split? Agenus's stock reverse split on the morning of Friday, April 12th 2024. The 1-20 reverse split was announced on Friday, April 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Agenus' major shareholders? Agenus' top institutional shareholders include Geode Capital Management LLC (2.06%), State Street Corp (1.99%), Walleye Capital LLC (0.85%) and Wellington Management Group LLP (0.37%). Insiders that own company stock include Agenus Inc, Garo H Armen and Steven J O'day. View institutional ownership trends. How do I buy shares of Agenus? Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Agenus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Agenus investors own include DiamondRock Hospitality (DRH), Waste Connections (WCN), American Water Works (AWK), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/08/2024Today12/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:AGEN CUSIP00847G70 CIK1098972 Webagenusbio.com Phone(781) 674-4400Fax781-674-4200Employees389Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$18.00 Low Stock Price Target$7.00 Potential Upside/Downside+253.4%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($11.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-245,760,000.00 Net Margins-145.89% Pretax Margin-145.89% Return on EquityN/A Return on Assets-85.68% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.19 Sales & Book Value Annual Sales$160.43 million Price / Sales0.41 Cash FlowN/A Price / Cash FlowN/A Book Value($7.78) per share Price / Book-0.36Miscellaneous Outstanding Shares23,459,000Free Float22,380,000Market Cap$66.39 million OptionableOptionable Beta1.25 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:AGEN) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.